ArticleVeterinary medicine and science2026
Therapeutic Effects of Matricaria chamomilla Extract in an Immunosuppressed Mouse Model of Cryptosporidiosis.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryptosporidiosis, caused by Cryptosporidium parvum, is an opportunistic protozoan infection that can lead to severe intestinal pathology in immunocompromised hosts. Despite extensive research, current chemotherapeutic options, such as nitazoxanide and paromomycin, remain suboptimal, underscoring the need for safe and effective alternatives. Chamomile (Matricaria chamomilla L.), known for its antioxidant, anti-inflammatory, and antiparasitic activities, has recently attracted attention as a potential phytotherapeutic agent.
methodsThis experimental study evaluated the therapeutic efficacy of a hydroalcoholic chamomile extract in immunosuppressed Swiss albino mice infected experimentally with C. parvum. Animals were divided into five groups: normal control, chamomile control, infected untreated, infected treated with paromomycin (100 mg/kg/day) and infected treated with chamomile extract (100 mg/kg/day). Oocyst shedding, intestinal histopathology and oxidative stress biomarkers were assessed at Days 0 (7 days post-infection), and 3, 7 and 11 post-treatment.
resultsChamomile treatment significantly reduced oocyst shedding compared with the untreated infected group (p < 0.05) and improved intestinal tissue architecture by attenuating villous atrophy, epithelial desquamation and inflammatory cell infiltration. Biochemical assays revealed that chamomile markedly increased TAC and GPx activity while reducing MDA levels. Although paromomycin showed a more rapid reduction in oocyst output, chamomile induced a gradual but sustained improvement with pronounced antioxidant and anti-inflammatory effects.
conclusionHydroalcoholic extract of M. chamomilla was associated with reduced oocyst shedding, improved intestinal histopathology, and enhanced antioxidant status in immunosuppressed mice infected with C. parvum, supporting its potential as an adjunctive phytotherapeutic approach that warrants further mechanistic, pharmacological and long-term investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.